ORGANOGENESIS HOLDINGS INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ORGANOGENESIS HOLDINGS INC. (ORGO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- ORGANOGENESIS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.05M, a 20.06% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.64M, a 7.99% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.06M, a 13.02% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.54M, a 1.01% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $13.30M, a 25.71% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $10.58M, a 17.59% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $9.00M, a 37.30% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $6.55M, a 69.57% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.05M 10-Q · filed 2026-08-06 | $6.69M derived: sum of 2 quarters · filed 2026-08-06 | ||||||
| 2026-03-31 | $3.64M 10-Q · filed 2026-08-06 | |||||||
| 2025-12-31 | $13.30M 10-K · filed 2026-02-26 | |||||||
| 2025-09-30 | $3.06M 10-Q · filed 2025-11-06 | $5.61M derived: sum of 2 quarters · filed 2026-08-06 | $8.97M derived: sum of 3 quarters · filed 2026-08-06 | |||||
| 2025-06-30 | $2.54M 10-Q · filed 2026-08-06 | $5.91M derived: sum of 2 quarters · filed 2026-08-06 | ||||||
| 2025-03-31 | $3.37M 10-Q · filed 2026-08-06 | |||||||
| 2024-12-31 | $10.58M 10-K · filed 2026-02-26 | |||||||
| 2024-09-30 | $2.71M 10-Q · filed 2025-11-06 | $5.28M derived: sum of 2 quarters · filed 2025-11-06 | $7.69M derived: sum of 3 quarters · filed 2025-11-06 | $10.05M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $2.57M 10-Q · filed 2025-11-06 | $4.97M derived: sum of 2 quarters · filed 2025-11-06 | $7.34M derived: sum of 3 quarters · filed 2026-02-26 | $9.76M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $2.41M 10-Q · filed 2025-11-06 | $4.77M derived: sum of 2 quarters · filed 2026-02-26 | $7.19M derived: sum of 3 quarters · filed 2026-02-26 | $9.49M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.78M derived: sum of 2 quarters · filed 2026-02-26 | $7.08M derived: sum of 3 quarters · filed 2026-02-26 | $9.00M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $2.42M 10-Q · filed 2024-11-12 | $4.72M derived: sum of 2 quarters · filed 2024-11-12 | $6.63M 10-Q · filed 2023-11-09 | $8.48M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $2.30M 10-Q · filed 2024-11-12 | $4.21M 10-Q · filed 2023-08-09 | $6.07M derived: sum of 3 quarters · filed 2025-02-27 | $7.77M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $1.91M 10-Q · filed 2024-11-12 | -$1.91M 10-Q · filed 2023-05-10 | $3.77M derived: sum of 2 quarters · filed 2025-02-27 | $5.47M derived: sum of 3 quarters · filed 2025-02-27 | $7.16M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.56M derived: sum of 2 quarters · filed 2025-02-27 | $5.25M derived: sum of 3 quarters · filed 2025-02-27 | $6.55M 10-K · filed 2025-02-27 | -$6.55M 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $1.70M 10-Q · filed 2023-11-09 | -$1.70M 10-Q · filed 2022-11-09 | $3.39M derived: sum of 2 quarters · filed 2023-11-09 | $4.70M 10-Q · filed 2023-11-09 | -$4.70M 10-Q · filed 2022-11-09 | $8.74M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | $1.69M 10-Q · filed 2023-08-09 | -$1.69M 10-Q · filed 2022-08-09 | $3.00M 10-Q · filed 2023-08-09 | -$3.00M 10-Q · filed 2022-08-09 | $7.03M derived: sum of 3 quarters · filed 2024-02-29 | $5.99M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-03-31 | -$1.30M 10-Q · filed 2023-05-10 | $5.34M derived: sum of 2 quarters · filed 2024-02-29 | $4.30M derived: sum of 3 quarters · filed 2024-02-29 | $3.26M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | $6.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $5.60M derived: sum of 2 quarters · filed 2024-02-29 | $4.56M derived: sum of 3 quarters · filed 2024-02-29 | $3.86M 10-K · filed 2024-02-29 | -$3.86M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | -$1.04M 10-Q · filed 2022-11-09 | -$2.08M derived: sum of 2 quarters · filed 2022-11-09 | -$2.78M 10-Q · filed 2022-11-09 | -$3.28M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | -$1.04M 10-Q · filed 2022-08-09 | -$1.74M 10-Q · filed 2022-08-09 | -$2.24M derived: sum of 3 quarters · filed 2023-03-01 | -$2.72M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | -$698.00K 10-Q · filed 2022-05-10 | -$1.20M derived: sum of 2 quarters · filed 2023-03-01 | -$1.68M derived: sum of 3 quarters · filed 2023-03-01 | -$2.15M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | -$497.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$983.00K derived: sum of 2 quarters · filed 2023-03-01 | -$1.45M derived: sum of 3 quarters · filed 2023-03-01 | -$1.66M 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | -$486.00K 10-Q · filed 2021-11-09 | -$955.00K derived: sum of 2 quarters · filed 2021-11-09 | -$1.16M 10-Q · filed 2021-11-09 | -$1.40M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | -$469.00K 10-Q · filed 2021-08-09 | -$678.00K 10-Q · filed 2021-08-09 | -$914.00K derived: sum of 3 quarters · filed 2022-03-01 | -$1.16M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | -$209.00K 10-Q · filed 2021-05-11 | -$445.00K derived: sum of 2 quarters · filed 2022-03-01 | -$687.00K derived: sum of 3 quarters · filed 2022-03-01 | -$921.00K derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | -$236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$478.00K derived: sum of 2 quarters · filed 2022-03-01 | -$712.00K derived: sum of 3 quarters · filed 2022-03-01 | -$936.00K 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | -$242.00K 10-Q · filed 2020-11-09 | -$476.00K derived: sum of 2 quarters · filed 2020-11-09 | -$700.00K 10-Q · filed 2020-11-09 | -$955.00K derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2019-06-30 | -$234.00K 10-Q · filed 2020-08-10 | -$458.00K 10-Q · filed 2020-08-10 | -$713.00K derived: sum of 3 quarters · filed 2021-03-16 | -$965.00K derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2019-03-31 | -$224.00K 10-Q · filed 2020-05-11 | -$479.00K derived: sum of 2 quarters · filed 2021-03-16 | -$731.00K derived: sum of 3 quarters · filed 2021-03-16 | -$982.00K derived: sum of 4 quarters · filed 2021-03-16 | ||||
| 2018-12-31 | -$255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$507.00K derived: sum of 2 quarters · filed 2021-03-16 | -$758.00K derived: sum of 3 quarters · filed 2021-03-16 | -$1.07M 10-K · filed 2021-03-16 | ||||
| 2018-09-30 | -$252.00K 10-Q · filed 2019-11-12 | -$503.00K derived: sum of 2 quarters · filed 2019-11-12 | -$820.00K 10-Q · filed 2019-11-12 | |||||
| 2018-06-30 | -$251.00K 10-Q · filed 2019-08-09 | -$568.00K derived: sum of 2 quarters · filed 2019-08-09 | ||||||
| 2018-03-31 | -$317.00K 10-Q · filed 2019-08-09 | |||||||
| 2017-12-31 | -$919.00K 10-K · filed 2020-03-09 | |||||||
| 2016-12-31 | -$473.00K 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |